The immunogenicity profiles of the recombinant hepatitis B vaccines commercially available in Pakistan were compared to Engerix-B® in a double-blind, prospective equivalence study. A total of 744 subjects (449 male, 295 female) of different age group and professions (randomly selected) of urban areas of Bahawalpur district were included in this study. Population was divided in six different groups (children, young and adult of either sex) and each group was administered (intramuscularly) one brand of vaccine (0, 1 and 6 month schedule). Children groups were vaccinated by 10 μg while young and adults groups by 20 μg of respective vaccine. The participants had blood samples taken (3-times; at the time of second dose, one and six months after third dose). The seroprotection; geometric mean titer (mIU mL-1) of six different vaccine used, were found maximum 1880.46±12.48 with Amvax B and minimum 1790.62±18.26 with Hepa-B-vac in children group, from 1897.43±17.26 (Engirex-B) to 1815.46±12.74 (Hepa-B-vac) in young group and from 1881.75±10.97 (Amvax-B®) to 1729.82±8.85 (Hepa-B-vac) in adult group. The antibody titers <10 mIU mL-1 were found highest (3.8%) with Hepa-B-vac® and lowest (2.4%) with Amvax-B® and Hepavax-Gene®. Antibody titers 10<100, 100<1000 and >1000 mIU mL-1 were observed 14.56 (Hepa-B-vac®) to 9.1% (Amvax-B®), 40.56 (Heberbiovac) to 39.15% (Hepavax-Gene) and 48.8 (Engirex-B) to 41.61% (Hepa-B-vac), respectively. The study concluded that all the recombinant hepatitis B vaccines tested were equipotent and similar in immunogenicity to Engerix-B® in the human urban population of Bahawalpur-Pakistan.
PDF References Citation
How to cite this article
Rifat-uz-Zaman, 2006. Comparative Immunogenicity of Commercially Available Recombinant Vaccines Against Hepatitis B in Human Urban Population of Bahawalpur District, Pakistan . Journal of Biological Sciences, 6: 1053-1058.
- Safary, A. and F. Andre, 1999. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine, 18: 57-67.
- Baldy, J.L., G.Z. de Lima, H.K. Morimoto, E.M. Reiche, T. Matsuo, E.D. de Mattos and L.C. Sudan, 2004. Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination. Rev. Inst. Med. Trop. Sao Paulo, 46: 103-107.
- Leroux-Roels, G., B. Abraham, M. Fourneau, N. Clercq and A. Safary, 2000. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents. Vaccine, 19: 937-942.
- Rifat-uz-Zaman, 2006. Prevalence of Hepatitis B and Hepatitis C viruses in human urban population of Bahawalpur District, Pakistan. J. Med. Sci., 6: 429-435.
- Szmuness, W., C.E. Stevens, E.A. Zang, E.J. Harley and A. Kellner, 1981. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report. Hepatology, 1: 377-385.